Lateral Canthal Lines Clinical Trial
Official title:
Dose Finding Study of Botulinum Neurotoxin Type A In Subjects With Crow's Feet (Lateral Canthal Lines)
| Verified date | May 2014 |
| Source | Anterios Inc. |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Food and Drug Administration |
| Study type | Interventional |
The purpose of this study is to establish the therapeutic range of ANT-1401 in the treatment of Crow's Feet.
| Status | Completed |
| Enrollment | 145 |
| Est. completion date | January 2014 |
| Est. primary completion date | December 2013 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 30 Years to 60 Years |
| Eligibility |
Inclusion Criteria: - 30 - 60 years of age - mild to moderate Crow's Feet wrinkles at rest - moderate to severe Crow's Feet wrinkles on contraction - willingness to refrain from any product affecting skin remodeling - female subjects must be not pregnant and non-lactating Exclusion Criteria: - history of peri-ocular surgery, brow lift or related procedures - procedures affecting the lateral canthal region in the prior 12 months - application of topical prescription medication to the treatment area - female subjects who are pregnant or are nursing a child |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Anterios Inc. |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Investigators Global Assessment Scale | Crow's Feet Wrinkle Scale | Week 4 | No |
| Secondary | Subject Self-Assessment score | Subjects self assessment of severity of Crow's Feet | up to 12 12 weeks | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02248844 -
Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea
|
||
| Completed |
NCT02195687 -
BOTOX® in the Treatment of Crow's Feet Lines in China
|
Phase 3 | |
| Completed |
NCT03721016 -
MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
|
Phase 3 | |
| Completed |
NCT03326856 -
ET-01 in Subjects With Lateral Canthal Lines
|
Phase 2 | |
| Completed |
NCT04157686 -
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
|
Phase 3 | |
| Completed |
NCT03923634 -
Princess® RICH for the Correction of Fine Lines
|
N/A | |
| Completed |
NCT03839693 -
ET-01 in Subjects With Lateral Canthal Lines, LCL-208
|
Phase 2 | |
| Completed |
NCT03732833 -
MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
|
Phase 3 | |
| Completed |
NCT00888914 -
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
|
Phase 2 | |
| Completed |
NCT04143854 -
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines
|
Phase 2 | |
| Completed |
NCT01358695 -
Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet
|
Phase 2 | |
| Completed |
NCT01124565 -
Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
|
Phase 2 | |
| Completed |
NCT00247559 -
Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)
|
Phase 2 | |
| Completed |
NCT01809964 -
Clinical Trial to Evaluate ANT-1401 in Crow's Feet
|
Phase 2 | |
| Completed |
NCT03911102 -
Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
|
Phase 2 | |
| Completed |
NCT00968825 -
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
|
Phase 2 | |
| Completed |
NCT04225260 -
Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
|
Phase 3 | |
| Completed |
NCT01064518 -
Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
|
Phase 2 | |
| Completed |
NCT00884234 -
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
|
Phase 2 | |
| Completed |
NCT04249687 -
Treatment of Moderate to Severe Lateral Canthal Lines
|
Phase 3 |